JP2024510927A5 - - Google Patents

Info

Publication number
JP2024510927A5
JP2024510927A5 JP2023553029A JP2023553029A JP2024510927A5 JP 2024510927 A5 JP2024510927 A5 JP 2024510927A5 JP 2023553029 A JP2023553029 A JP 2023553029A JP 2023553029 A JP2023553029 A JP 2023553029A JP 2024510927 A5 JP2024510927 A5 JP 2024510927A5
Authority
JP
Japan
Prior art keywords
alkyl
exist
substituted
pabc
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023553029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510927A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/018534 external-priority patent/WO2022187370A1/en
Publication of JP2024510927A publication Critical patent/JP2024510927A/ja
Publication of JP2024510927A5 publication Critical patent/JP2024510927A5/ja
Pending legal-status Critical Current

Links

JP2023553029A 2021-03-03 2022-03-02 抗体-薬物コンジュゲートのための分岐リンカー及びその使用方法 Pending JP2024510927A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163156156P 2021-03-03 2021-03-03
US63/156,156 2021-03-03
US202163186581P 2021-05-10 2021-05-10
US63/186,581 2021-05-10
US202163214540P 2021-06-24 2021-06-24
US63/214,540 2021-06-24
US202163237450P 2021-08-26 2021-08-26
US63/237,450 2021-08-26
PCT/US2022/018534 WO2022187370A1 (en) 2021-03-03 2022-03-02 Branched linkers for antibody-drug conjugates and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024510927A JP2024510927A (ja) 2024-03-12
JP2024510927A5 true JP2024510927A5 (cg-RX-API-DMAC10.html) 2025-03-06

Family

ID=83155529

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023553029A Pending JP2024510927A (ja) 2021-03-03 2022-03-02 抗体-薬物コンジュゲートのための分岐リンカー及びその使用方法

Country Status (9)

Country Link
US (1) US20240148883A1 (cg-RX-API-DMAC10.html)
EP (1) EP4301415A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024510927A (cg-RX-API-DMAC10.html)
KR (1) KR20230165207A (cg-RX-API-DMAC10.html)
AU (1) AU2022230398A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023017670A2 (cg-RX-API-DMAC10.html)
CA (1) CA3210473A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023010099A (cg-RX-API-DMAC10.html)
WO (1) WO2022187370A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4739347A1 (en) * 2023-07-07 2026-05-13 Solve Therapeutics, Inc. Conjugates of drug units and targeting units and precursor compounds thereof
EP4791439A1 (en) * 2023-10-13 2026-08-19 Sutro Biopharma, Inc. Dual payload antibody drug conjugates
CN122374045A (zh) * 2023-10-16 2026-07-10 蜂鸟生物科技私人有限公司 Her2结合分子
WO2025083071A2 (en) * 2023-10-16 2025-04-24 Hummingbird Bioscience Pte. Ltd. Antibody-drug conjugates
WO2026080692A1 (en) * 2024-10-09 2026-04-16 Sutro Biopharma, Inc. Branched beta-glucuronide linker-payloads, protein conjugates thereof, and methods thereof
WO2026150353A2 (en) 2025-01-11 2026-07-16 Biohaven Therapeutics Ltd. Antibody-drug conjugates for delivering cytotoxic agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9310374B2 (en) * 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
WO2017083306A1 (en) * 2015-11-09 2017-05-18 R.P. Scherer Technologies, Llc Anti-cd22 antibody-maytansine conjugates and methods of use thereof
HUE067016T2 (hu) * 2015-11-25 2024-09-28 Ligachem Biosciences Inc Önfeláldozó csoportokat tartalmazó konjugátumok és ezekkel kapcsolos eljárások
EP3700577A1 (en) * 2017-10-23 2020-09-02 Mablink Bioscience Ligand-drug-conjugate comprising a single molecular weight polysarcosine
WO2019113248A1 (en) * 2017-12-07 2019-06-13 The Regents Of The University Of California Anti-upar antibody-drug conjugates and methods of use thereof
MX2020006010A (es) * 2017-12-11 2020-10-16 Triphase Res And Development Iii Corp Conjugados de anticuerpo anti-cd22-maitansina, combinaciones y metodos de uso de los mismos.
WO2020154437A1 (en) * 2019-01-23 2020-07-30 R.P. Scherer Technologies, Llc Glycoside-containing peptide linkers for antibody-drug conjugates
JP7546755B2 (ja) * 2020-10-19 2024-09-06 ジアンス・コンテンポラリー・アンプレックス・テクノロジー・リミテッド 電池、電力利用装置及び電池の調製方法、設備

Similar Documents

Publication Publication Date Title
JP2022518743A5 (cg-RX-API-DMAC10.html)
JP2024529466A5 (cg-RX-API-DMAC10.html)
RU2628311C2 (ru) Молекула одноцепочечной нуклеиновой кислоты для контроля экспрессии генов
CN101641372B (zh) 模板固定的肽模拟物
JP2021502120A5 (cg-RX-API-DMAC10.html)
JPH08501071A (ja) 1,5−アンヒドロヘキシトールヌクレオシド類似体および該類似体の医薬としての使用
JP2022543231A5 (cg-RX-API-DMAC10.html)
JP2020143066A5 (cg-RX-API-DMAC10.html)
BG61485B1 (bg) N горе 4-оксикарбонил заместени 5'-деокси-5-флуороцитидини
KR950704261A (ko) 부신피질자극호르몬-방출 인자(crf) 길항물질 활성을 갖는 피라졸 및 피라졸로피리미딘(pyrazoles and pyrazolpyrimidnes having crf antagonist activity)
JP2019501214A5 (cg-RX-API-DMAC10.html)
KR20140024833A (ko) 신규한 시티딘계 대사길항제의 고분자 유도체
JP2020525502A5 (cg-RX-API-DMAC10.html)
WO2009092295A1 (zh) 一组格尔德霉素衍生物及其制备方法
CN114805212B (zh) 用于递送治疗或预防剂的脂质和脂质组合物
CN112574272A (zh) 一种灵芝酸a衍生物的制备及其应用
WO2024005460A1 (ko) 자가-희생기를 포함하는 화합물 및 이를 포함하는 리간드-약물 접합체
CA2602755A1 (en) Antibacterial amide-macrocycles v
AU2007345099B2 (en) The tetracyclic anthraquinones possessing anti-cancer effect
JP2023551203A5 (cg-RX-API-DMAC10.html)
CN102659843B (zh) D,l-鸟嘌呤核苷类似物单磷酸酯及其制备方法和应用
US20120308646A1 (en) Tetracyclic anthraquinones possessing anti-cancer properties
Arosio et al. Click chemistry to functionalise peptidomimetics
Komatani et al. Solid-phase total synthesis of sandramycin and its analogues
Zhang et al. Synthesis and biological evaluation of novel quaternary ammonium antibody drug conjugates based on camptothecin derivatives